Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.28
TFX's Cash to Debt is ranked higher than
50% of the 509 Companies
in the Global Medical Devices industry.

( Industry Median: 2.15 vs. TFX: 0.28 )
TFX' s 10-Year Cash to Debt Range
Min: 0.07   Max: 0.61
Current: 0.28

0.07
0.61
Equity to Asset 0.48
TFX's Equity to Asset is ranked higher than
56% of the 472 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. TFX: 0.48 )
TFX' s 10-Year Equity to Asset Range
Min: 0.32   Max: 0.51
Current: 0.48

0.32
0.51
Interest Coverage 4.35
TFX's Interest Coverage is ranked lower than
55% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 365.56 vs. TFX: 4.35 )
TFX' s 10-Year Interest Coverage Range
Min: 2.18   Max: 9.07
Current: 4.35

2.18
9.07
F-Score: 6
Z-Score: 2.93
M-Score: -2.66
WACC vs ROIC
9.32%
8.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 15.48
TFX's Operating margin (%) is ranked higher than
89% of the 485 Companies
in the Global Medical Devices industry.

( Industry Median: 4.94 vs. TFX: 15.48 )
TFX' s 10-Year Operating margin (%) Range
Min: -6.28   Max: 16.28
Current: 15.48

-6.28
16.28
Net-margin (%) 10.20
TFX's Net-margin (%) is ranked higher than
87% of the 485 Companies
in the Global Medical Devices industry.

( Industry Median: 2.98 vs. TFX: 10.20 )
TFX' s 10-Year Net-margin (%) Range
Min: -12.25   Max: 21.66
Current: 10.2

-12.25
21.66
ROE (%) 9.64
TFX's ROE (%) is ranked higher than
83% of the 476 Companies
in the Global Medical Devices industry.

( Industry Median: 3.46 vs. TFX: 9.64 )
TFX' s 10-Year ROE (%) Range
Min: -10.11   Max: 21.44
Current: 9.64

-10.11
21.44
ROA (%) 4.57
TFX's ROA (%) is ranked higher than
80% of the 512 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. TFX: 4.57 )
TFX' s 10-Year ROA (%) Range
Min: -4.96   Max: 8.55
Current: 4.57

-4.96
8.55
ROC (Joel Greenblatt) (%) 34.27
TFX's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 509 Companies
in the Global Medical Devices industry.

( Industry Median: 5.54 vs. TFX: 34.27 )
TFX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13.47   Max: 35.77
Current: 34.27

-13.47
35.77
Revenue Growth (3Y)(%) 2.70
TFX's Revenue Growth (3Y)(%) is ranked higher than
71% of the 342 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. TFX: 2.70 )
TFX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -11   Max: 17.3
Current: 2.7

-11
17.3
EBITDA Growth (3Y)(%) 5.30
TFX's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. TFX: 5.30 )
TFX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -7.8   Max: 15.4
Current: 5.3

-7.8
15.4
EPS Growth (3Y)(%) 12.20
TFX's EPS Growth (3Y)(%) is ranked higher than
86% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: -2.00 vs. TFX: 12.20 )
TFX' s 10-Year EPS Growth (3Y)(%) Range
Min: -17.4   Max: 16.1
Current: 12.2

-17.4
16.1
» TFX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

TFX Guru Trades in Q2 2014

Joel Greenblatt 17,351 sh (+49.54%)
Jim Simons 375,400 sh (+13.80%)
John Keeley 3,820 sh (unchged)
Murray Stahl 6,679 sh (unchged)
Chuck Royce 309,700 sh (unchged)
Robert Olstein 63,000 sh (-3.08%)
Paul Tudor Jones 2,800 sh (-3.45%)
Third Avenue Management 270,465 sh (-26.84%)
Manning & Napier Advisors, Inc 2,190 sh (-99.79%)
» More
Q3 2014

TFX Guru Trades in Q3 2014

Joel Greenblatt 284,633 sh (+1540.44%)
Paul Tudor Jones 3,556 sh (+27.00%)
Manning & Napier Advisors, Inc 2,190 sh (unchged)
Chuck Royce 309,700 sh (unchged)
Robert Olstein 63,000 sh (unchged)
John Keeley 3,820 sh (unchged)
Jim Simons 360,000 sh (-4.10%)
Murray Stahl 6,384 sh (-4.42%)
Third Avenue Management 175,094 sh (-35.26%)
» More
Q4 2014

TFX Guru Trades in Q4 2014

Paul Tudor Jones 6,731 sh (+89.29%)
Jim Simons 546,400 sh (+51.78%)
Joel Greenblatt 359,093 sh (+26.16%)
Manning & Napier Advisors, Inc 2,190 sh (unchged)
Murray Stahl 6,384 sh (unchged)
Chuck Royce 309,700 sh (unchged)
John Keeley 3,070 sh (-19.63%)
Third Avenue Management 56,069 sh (-67.98%)
Robert Olstein 8,000 sh (-87.30%)
» More
Q1 2015

TFX Guru Trades in Q1 2015

Manning & Napier Advisors, Inc Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 30.70
TFX's P/E(ttm) is ranked higher than
86% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TFX: 30.70 )
TFX' s 10-Year P/E(ttm) Range
Min: 4.99   Max: 258.41
Current: 30.7

4.99
258.41
Forward P/E 17.45
TFX's Forward P/E is ranked higher than
93% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TFX: 17.45 )
N/A
PE(NRI) 29.70
TFX's PE(NRI) is ranked higher than
88% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TFX: 29.70 )
TFX' s 10-Year PE(NRI) Range
Min: 13.8   Max: 74.07
Current: 29.7

13.8
74.07
P/B 2.60
TFX's P/B is ranked higher than
76% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. TFX: 2.60 )
TFX' s 10-Year P/B Range
Min: 1.04   Max: 2.64
Current: 2.6

1.04
2.64
P/S 3.16
TFX's P/S is ranked higher than
64% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 4.16 vs. TFX: 3.16 )
TFX' s 10-Year P/S Range
Min: 0.71   Max: 3.1
Current: 3.16

0.71
3.1
PFCF 26.00
TFX's PFCF is ranked higher than
89% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TFX: 26.00 )
TFX' s 10-Year PFCF Range
Min: 5.92   Max: 51.16
Current: 26

5.92
51.16
POCF 19.51
TFX's POCF is ranked higher than
87% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 1303.50 vs. TFX: 19.51 )
TFX' s 10-Year POCF Range
Min: 5.23   Max: 27.24
Current: 19.51

5.23
27.24
EV-to-EBIT 20.37
TFX's EV-to-EBIT is ranked higher than
88% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 151.63 vs. TFX: 20.37 )
TFX' s 10-Year EV-to-EBIT Range
Min: -39.5   Max: 23.7
Current: 20.37

-39.5
23.7
Shiller P/E 30.10
TFX's Shiller P/E is ranked higher than
92% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TFX: 30.10 )
TFX' s 10-Year Shiller P/E Range
Min: 10.28   Max: 30.1
Current: 30.1

10.28
30.1
Current Ratio 1.66
TFX's Current Ratio is ranked higher than
56% of the 508 Companies
in the Global Medical Devices industry.

( Industry Median: 2.58 vs. TFX: 1.66 )
TFX' s 10-Year Current Ratio Range
Min: 1.46   Max: 4.72
Current: 1.66

1.46
4.72
Quick Ratio 1.13
TFX's Quick Ratio is ranked higher than
55% of the 508 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. TFX: 1.13 )
TFX' s 10-Year Quick Ratio Range
Min: 0.86   Max: 3.62
Current: 1.13

0.86
3.62
Days Inventory 140.62
TFX's Days Inventory is ranked higher than
74% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 169.25 vs. TFX: 140.62 )
TFX' s 10-Year Days Inventory Range
Min: 74.32   Max: 171.38
Current: 140.62

74.32
171.38
Days Sales Outstanding 54.30
TFX's Days Sales Outstanding is ranked higher than
86% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 82.25 vs. TFX: 54.30 )
TFX' s 10-Year Days Sales Outstanding Range
Min: 54.3   Max: 98.44
Current: 54.3

54.3
98.44

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.09
TFX's Dividend Yield is ranked lower than
63% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. TFX: 1.09 )
TFX' s 10-Year Dividend Yield Range
Min: 1.12   Max: 3.48
Current: 1.09

1.12
3.48
Dividend Payout 0.33
TFX's Dividend Payout is ranked higher than
91% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TFX: 0.33 )
TFX' s 10-Year Dividend Payout Range
Min: 0.17   Max: 3.58
Current: 0.33

0.17
3.58
Yield on cost (5-Year) 1.10
TFX's Yield on cost (5-Year) is ranked lower than
63% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. TFX: 1.10 )
TFX' s 10-Year Yield on cost (5-Year) Range
Min: 1.12   Max: 3.48
Current: 1.1

1.12
3.48
Share Buyback Rate -4.40
TFX's Share Buyback Rate is ranked higher than
69% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -1.40 vs. TFX: -4.40 )
TFX' s 10-Year Share Buyback Rate Range
Min: 1   Max: -4.4
Current: -4.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.00
TFX's Price/DCF (Projected) is ranked higher than
90% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TFX: 2.00 )
TFX' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 2.03
Current: 2

0.6
2.03
Price/Median PS Value 2.00
TFX's Price/Median PS Value is ranked higher than
56% of the 560 Companies
in the Global Medical Devices industry.

( Industry Median: 1.30 vs. TFX: 2.00 )
TFX' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 1.84
Current: 2

0.48
1.84
Earnings Yield (Greenblatt) 4.90
TFX's Earnings Yield (Greenblatt) is ranked higher than
86% of the 491 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. TFX: 4.90 )
TFX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.2   Max: 10.8
Current: 4.9

4.2
10.8
Forward Rate of Return (Yacktman) 1.64
TFX's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: 3.98 vs. TFX: 1.64 )
TFX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.1   Max: 20.9
Current: 1.64

3.1
20.9

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:TBH.Germany,
Teleflex Inc is a Delaware Corporation incorporated in 1943. The Company is a provider of medical technology products that provides clinical benefits, improve patient and provider safety and reduce total procedural costs. It designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It sells its products to hospitals and healthcare providers in more than 150 countries through a combination of its direct sales force and distributors. The Company manufactures its products at 27 manufacturing sites, with major manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. It provides a broad-based platform of products, which it categorizes into four groups namely Critical Care, Surgical Care, Cardiac Care and OEM and Development Services. It is a provider of specialty products for critical care, which is predominantly comprised of single-use products. The large majority of sales for single-use products are made to the hospital/healthcare provider market, with a smaller percentage sold to alternate sites. The Company's surgical products include ligation and closure products, including appliers, clips and sutures used in a variety of surgical procedures; access ports used in minimally invasive surgical procedures, including robotic surgery; and fluid management products used for chest drainage. The Company's surgical products also include hand-held instruments for general and specialty surgical procedures. It markets surgical products under the Deknatel, Pleur-evac, Pilling, Taut and Weck brand names. Products in Cardiac Care category include diagnostic catheters and capital equipment. The Company's diagnostic catheters include thermodilution and wedge pressure catheters; specialized angiographic catheters, such as Berman and Reverse Berman catheters; therapeutic delivery catheters, such as temporary pacing catheters; sheaths for femoral and trans-radial aortic access used in diagnostic and therapeutic procedures; and intra-aortic balloon, or IAB, catheters. Capital equipment includes its intra-aortic balloon pump, or IABP, consoles. IABP products are used to augment oxygen delivery to the cardiac muscle and reduce the oxygen demand after cardiac surgery, serious heart attack or interventional procedures. The IAB and IABP product lines feature the AutoCAT 2 WAVE console and the FiberOptix catheter, which together utilize fiber optic technology for arterial pressure signal acquisition and enable the patented WAVE timing algorithm to support the broadest range of patient heart rhythms, including severely arrhythmic patients. The Company's OEM division, which includes the TFX OEM(r) and Deknatel(r) OEM nameplates, provides custom-engineered extrusions, diagnostic and interventional catheters, sheath/dilator sets (introducers) and kits, sutures, perfo
» More Articles for TFX

Headlines

Articles On GuruFocus.com
Teleflex Declares Its Quarter Four Results Feb 24 2015 
Third Avenue Management Update Aug 31 2013 
My Dividend Portfolio Looks Much Better than I Expected Jun 03 2013 
Teleflex Incorporated: Successful Transition into Pure-Play Medical Device Manufacturer Nov 19 2012 
5 Healthcare Stocks You Should Know About Mar 31 2012 
Teleflex: High Upside Potential This Year Mar 27 2012 
5 Healthcare Stocks to Consider for 2012 Mar 27 2012 
Third Avenue Management Buys Lowes, Teleflex, American Eagle Outfitters, Tellabs, Sells Pharmaceutic Nov 17 2011 
Teleflex Inc. Reports Operating Results (10-Q) Oct 27 2010 
Teleflex Inc. Reports Operating Results (10-Q) Jul 23 2010 

More From Other Websites
Medical Equipment Stocks Are Ready to Break Out Apr 22 2015
Teleflex to Present at the 6th European Conference of Interventional Oncology (ECIO) Apr 20 2015
Teleflex to Present at the 6th European Conference of Interventional Oncology (ECIO) Apr 20 2015
Teleflex Announces First Quarter 2015 Earnings Conference Call Information Apr 16 2015
Teleflex Announces First Quarter 2015 Earnings Conference Call Information Apr 16 2015
Teleflex to Present at European Association of Urology’s 30th Annual Congress Mar 22 2015
Teleflex to Present at European Association of Urology’s 30th Annual Congress Mar 19 2015
Teleflex Incorporated Signs New Agreements with Premier, Inc. for Endomechanical (Ligation and... Mar 16 2015
First Clinical Laparoscopic Procedure Using Teleflex’s New, Less Invasive Percuvance™... Mar 16 2015
First Clinical Laparoscopic Procedure Using Teleflex’s New, Less Invasive Percuvance™... Mar 16 2015
Teleflex to focus on Arrow® advanced interventional access solutions at European Vascular Course Mar 05 2015
Teleflex Incorporated Signs New Agreements with Premier, Inc. for Endomechanical (Ligation and... Mar 02 2015
TELEFLEX INC Financials Feb 27 2015
Teleflex Hits 52-Week High on Strong Q4, Strategic Deals - Analyst Blog Feb 24 2015
Teleflex to Present at Barclays Global Healthcare Conference Feb 24 2015
Teleflex to Present at Barclays Global Healthcare Conference Feb 24 2015
Medical Stocks Lead New Highs On Merger News Feb 23 2015
Teleflex upgraded by Barclays Feb 23 2015
10-K for Teleflex, Inc. Feb 22 2015
Teleflex Announces Quarterly Dividend Feb 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK